Skip to main content
Erschienen in: Clinical Orthopaedics and Related Research® 7/2010

01.07.2010 | Case Reports

Case Reports: Subtrochanteric Femoral Stress Fractures after Prolonged Alendronate Therapy

verfasst von: Katerina Cermak, MD, Felix Shumelinsky, MD, Jean Alexiou, MD, Michael J. Gebhart, MD

Erschienen in: Clinical Orthopaedics and Related Research® | Ausgabe 7/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

Alendronate is known for its ability to reduce bone loss in osteoporotic and osseous metastatic conditions. Its long-term effects remain unclear although several reports describe cases of proximal femur stress fractures associated with long-term alendronate use.

Case Description

We report the cases of four women who sustained low-energy subtrochanteric or femoral shaft stress fractures while being on alendronate therapy for more than 5 years. All radiographs showed typical patterns consisting of a transverse fracture line with external cortical bone reaction and medial cortical spike. Alendronate discontinuation along with nonoperative treatment was sufficient for one patient, whereas surgical stabilization was required in three patients.

Literature Review

The side effects of alendronate therapy include osteonecrosis of the jaw, esophageal irritation, and musculoskeletal pain. Several cases of insufficiency femoral fractures associated with prolonged alendronate use have been reported. Their radiographic pattern and clinical presentation are consistent with our observations. Although various hypotheses have been suggested, the physiopathogenesis of these stress fractures is not completely understood.

Purposes and Clinical Relevance

Although bisphosphonates play an important role in preventing pathologic fractures in patients with cancer, these subtrochanteric stress fractures associated with prolonged use of alendronate should not be ignored.
Literatur
1.
Zurück zum Zitat Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res. 2009;24:1095–1102.CrossRefPubMed Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res. 2009;24:1095–1102.CrossRefPubMed
2.
Zurück zum Zitat Allen MR, Gineyts E, Leeming DJ, Burr DB, Delmas PD. Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra. Osteoporos Int. 2008;19:329–337.CrossRefPubMed Allen MR, Gineyts E, Leeming DJ, Burr DB, Delmas PD. Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra. Osteoporos Int. 2008;19:329–337.CrossRefPubMed
3.
Zurück zum Zitat Aspenberg P. Bisphosphonate-induced fractures: nature strikes back? Acta Orthop. 2008;79:459–460.CrossRefPubMed Aspenberg P. Bisphosphonate-induced fractures: nature strikes back? Acta Orthop. 2008;79:459–460.CrossRefPubMed
4.
Zurück zum Zitat Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535–1541.CrossRefPubMed Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535–1541.CrossRefPubMed
5.
Zurück zum Zitat Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR; FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296:2927–2938.CrossRefPubMed Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR; FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296:2927–2938.CrossRefPubMed
6.
Zurück zum Zitat Blaimont P, Halleux P, Jedwab J. [Distribution of bony restraints in the femur] [in French]. Rev Chir Orthop Reparatrice Appar Mot. 1968;54:303–319.PubMed Blaimont P, Halleux P, Jedwab J. [Distribution of bony restraints in the femur] [in French]. Rev Chir Orthop Reparatrice Appar Mot. 1968;54:303–319.PubMed
7.
Zurück zum Zitat Butler JE, Brown SL, McConnell BG. Subtrochanteric stress fractures in runners. Am J Sports Med. 1982;10:228–232.CrossRefPubMed Butler JE, Brown SL, McConnell BG. Subtrochanteric stress fractures in runners. Am J Sports Med. 1982;10:228–232.CrossRefPubMed
8.
Zurück zum Zitat Currey JD. Effects of differences in mineralization on the mechanical properties of bone. Philos Trans R Soc Lond B Biol Sci. 1984;304:509–518.CrossRefPubMed Currey JD. Effects of differences in mineralization on the mechanical properties of bone. Philos Trans R Soc Lond B Biol Sci. 1984;304:509–518.CrossRefPubMed
9.
Zurück zum Zitat Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83:1032–1045.CrossRefPubMed Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83:1032–1045.CrossRefPubMed
10.
Zurück zum Zitat Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM; Fracture Intervention Trial Long-Term Extension Research Group. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res. 2004;19:1259–1269.CrossRefPubMed Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM; Fracture Intervention Trial Long-Term Extension Research Group. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res. 2004;19:1259–1269.CrossRefPubMed
11.
Zurück zum Zitat Esterberg J, Kassim RA, Redmon J, Coad J, Macari GS, Saleh KJ. Hip pain in a case of hypophosphatemic osteomalacia. Am J Orthop. 2003;32:455–458.PubMed Esterberg J, Kassim RA, Redmon J, Coad J, Macari GS, Saleh KJ. Hip pain in a case of hypophosphatemic osteomalacia. Am J Orthop. 2003;32:455–458.PubMed
12.
Zurück zum Zitat Garbuio P, Pernin JN. The biomechanics of the hip and hip implants. Cahier d’enseignement de la SOFCOT. 1999;69:37–48. Garbuio P, Pernin JN. The biomechanics of the hip and hip implants. Cahier d’enseignement de la SOFCOT. 1999;69:37–48.
13.
Zurück zum Zitat Geusens P. Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment. Curr Osteoporos Rep. 2009;7:12–17.CrossRefPubMed Geusens P. Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment. Curr Osteoporos Rep. 2009;7:12–17.CrossRefPubMed
14.
Zurück zum Zitat Goh SK, Yang KY, Koh JS, Wong MK, Chua SY, Chua DT, Howe TS. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br. 2007;89:349–353.CrossRefPubMed Goh SK, Yang KY, Koh JS, Wong MK, Chua SY, Chua DT, Howe TS. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br. 2007;89:349–353.CrossRefPubMed
15.
Zurück zum Zitat Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury. 2008;39:224–231.CrossRefPubMed Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury. 2008;39:224–231.CrossRefPubMed
16.
Zurück zum Zitat Leinberry CF, McShane RB, Stewart WG Jr, Hume EL. A displaced subtrochanteric stress fracture in a young amenorrheic athlete. Am J Sports Med. 1992;20:485–487.CrossRefPubMed Leinberry CF, McShane RB, Stewart WG Jr, Hume EL. A displaced subtrochanteric stress fracture in a young amenorrheic athlete. Am J Sports Med. 1992;20:485–487.CrossRefPubMed
17.
Zurück zum Zitat Lenart BA, Neviaser AS, Lyman S, Chang CC, Edobor-Osula F, Steele B, van der Meulen MC, Lorich DG, Lane JM. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int. 2009;20:1353–1362.CrossRefPubMed Lenart BA, Neviaser AS, Lyman S, Chang CC, Edobor-Osula F, Steele B, van der Meulen MC, Lorich DG, Lane JM. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int. 2009;20:1353–1362.CrossRefPubMed
18.
Zurück zum Zitat Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone. 2001;28:524–531.CrossRefPubMed Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone. 2001;28:524–531.CrossRefPubMed
19.
Zurück zum Zitat Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008;22:346–350.CrossRefPubMed Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008;22:346–350.CrossRefPubMed
20.
Zurück zum Zitat Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90:1294–1301.CrossRefPubMed Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90:1294–1301.CrossRefPubMed
21.
Zurück zum Zitat Orcel P, de Vernejoul MC, Prier A, Miravet L, Kuntz D, Kaplan G. Stress fractures of the lower limbs in osteoporotic patients treated with fluoride. J Bone Miner Res. 1990;5(suppl 1):S191–S194.PubMed Orcel P, de Vernejoul MC, Prier A, Miravet L, Kuntz D, Kaplan G. Stress fractures of the lower limbs in osteoporotic patients treated with fluoride. J Bone Miner Res. 1990;5(suppl 1):S191–S194.PubMed
22.
23.
Zurück zum Zitat Pauwels F. Die Bedeutung der Bauprinzipien des Stutz- und Bewegungsapparates für die Beanspruchung der Rohrenknochen; erster Beitrag zur funktionellen Anatomie und kausalen Morphologie des Stutzapparates. Z Anat Entwicklungsgesch. 1948;114:129–166.CrossRefPubMed Pauwels F. Die Bedeutung der Bauprinzipien des Stutz- und Bewegungsapparates für die Beanspruchung der Rohrenknochen; erster Beitrag zur funktionellen Anatomie und kausalen Morphologie des Stutzapparates. Z Anat Entwicklungsgesch. 1948;114:129–166.CrossRefPubMed
24.
Zurück zum Zitat Sayed-Noor AS, Sjoden GO. Subtrochanteric displaced insufficiency fracture after long-term alendronate therapy: a case report. Acta Orthop. 2008;79:565–567.CrossRefPubMed Sayed-Noor AS, Sjoden GO. Subtrochanteric displaced insufficiency fracture after long-term alendronate therapy: a case report. Acta Orthop. 2008;79:565–567.CrossRefPubMed
25.
Zurück zum Zitat Sayed-Noor AS, Sjoden GO. Case reports: two femoral insufficiency fractures after long-term alendronate therapy. Clin Orthop Relat Res. 2009;467:1921–1926.CrossRefPubMed Sayed-Noor AS, Sjoden GO. Case reports: two femoral insufficiency fractures after long-term alendronate therapy. Clin Orthop Relat Res. 2009;467:1921–1926.CrossRefPubMed
26.
Zurück zum Zitat Schnitzler CM, Wing JR, Gear KA, Robson HJ. Bone fragility of the peripheral skeleton during fluoride therapy for osteoporosis. Clin Orthop Relat Res. 1990;261:268–275.PubMed Schnitzler CM, Wing JR, Gear KA, Robson HJ. Bone fragility of the peripheral skeleton during fluoride therapy for osteoporosis. Clin Orthop Relat Res. 1990;261:268–275.PubMed
27.
Zurück zum Zitat Somford MP, Draijer FW, Thomassen BJ, Chavassieux PM, Boivin G, Papapoulos SE. Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. J Bone Miner Res. 2009;24:1736–1740. CrossRefPubMed Somford MP, Draijer FW, Thomassen BJ, Chavassieux PM, Boivin G, Papapoulos SE. Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. J Bone Miner Res. 2009;24:1736–1740. CrossRefPubMed
28.
Zurück zum Zitat Tosteson AN, Burge RT, Marshall DA, Lindsay R. Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations. Am J Manag Care. 2008;14:605–615.PubMed Tosteson AN, Burge RT, Marshall DA, Lindsay R. Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations. Am J Manag Care. 2008;14:605–615.PubMed
29.
Zurück zum Zitat Visekruna M, Wilson D, McKiernan FE. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab. 2008;93:2948–2952.CrossRefPubMed Visekruna M, Wilson D, McKiernan FE. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab. 2008;93:2948–2952.CrossRefPubMed
Metadaten
Titel
Case Reports: Subtrochanteric Femoral Stress Fractures after Prolonged Alendronate Therapy
verfasst von
Katerina Cermak, MD
Felix Shumelinsky, MD
Jean Alexiou, MD
Michael J. Gebhart, MD
Publikationsdatum
01.07.2010
Verlag
Springer-Verlag
Erschienen in
Clinical Orthopaedics and Related Research® / Ausgabe 7/2010
Print ISSN: 0009-921X
Elektronische ISSN: 1528-1132
DOI
https://doi.org/10.1007/s11999-009-1192-0

Weitere Artikel der Ausgabe 7/2010

Clinical Orthopaedics and Related Research® 7/2010 Zur Ausgabe

Symposium: Gender-specific Issues in Orthopaedic Surgery

Influence of Gender on Age of Treatment with TKA and Functional Outcome

Symposium: Gender-specific Issues in Orthopaedic Surgery

The Classic: The Etiology of Fractured Hips in Females

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.